During a live event, Omid Hamid, MD, discussed the logistics and multidisciplinary process of using tumor-infiltrating ...

Triple-leveraged ETFs aren’t for everyone, but if you believe biotech is about to break out, Direxion Daily S&P Biotech Bull ...

We came across a bullish thesis on Genmab A/S on Gabriel Koh’s Substack. In this article, we will summarize the bulls’ thesis ...

Among other things, we talked about President Trump’s “most-favored nations” policy on drug pricing and why Regeneron is the ...

The company will prioritise investment for in-house innovation over large M&A deals, bucking the trend across pharma.

Even with breakthroughs, treatment for advanced squamous cell carcinoma is more complex. Patients often need more than one treatment. Many patients with this advanced cancer are cared for by a team of ...

Measles, which was declared to be eliminated in 2000 in the United States, has seen a resurgence, with more than 2,000 cases ...

NEXSTAR — A dietary supplement meant to improve brain function and boost one’s metabolism is under recall after it was found ...

ARCALYST- (rilonacept) 2025 net product revenue of $677.5 million (unaudited), representing ~62% year-over-year growth -- ARCALYST 2026 net product revenue expected to be $900 - $920 million -- KPL-38 ...

Immuneering Corporation stays a Strong Buy: pancreatic cancer combo shows 64% 12‑mo OS, strong safety, and clear catalysts ...